Company / Operating Cash Flow
PULSE BIOSCIENCES, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$54.1M
FY2025
5-year range
-$54.1M / -$36.3M
FY2021-FY2025
Trend
-48.9%
vs FY2024
Sector context
#153 of 164
Health Care
What the data says
Among 164 Health Care companies, PULSE BIOSCIENCES, INC. is in the bottom 7% for operating cash flow. Declined from -$47M to -$54M over the past 2 years.
Based on SEC 10-K filings.
-$54M in FY2025.
Declined from -$47M to -$54M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 164This company -$54.1M Sector average $1.0B
▼
-105.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 48.9% year-over-year.
- Ranks #153 out of 164 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$54.1M | -48.9% |
| FY2024 | -$36.3M | +22.7% |
| FY2023 | -$47.0M | +0.0% |
| FY2022 | -$47.0M | +13.1% |
| FY2021 | -$54.1M | -53.0% |
| FY2020 | -$35.4M | -3.5% |
| FY2019 | -$34.2M | -43.1% |
| FY2018 | -$23.9M | -115.5% |
| FY2017 | -$11.1M | -37.7% |
| FY2016 | -$8.1M | -142.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026